Targeting glmS Ribozyme with Chimeric Antisense Oligonucleotides for Antibacterial Drug Development

Area of Science:

• Antimicrobial drug development
• Molecular biology
• Bacterial genetics

Background:

• Rising multidrug-resistant bacteria necessitate novel antibacterial agents.
• Staphylococcus aureus is a frequent cause of hospital-acquired infections.
• Antisense oligonucleotides offer a potential therapeutic approach.

Purpose of the Study:

• To develop and evaluate chimeric antisense oligonucleotides for inhibiting Staphylococcus aureus growth.
• To investigate the potential of targeting the glmS ribozyme and nagA gene.
• To assess the efficacy of cell-penetrating oligopeptide delivery.

Main Methods:

• Bioinformatic analysis of the glmS ribozyme and alternative metabolic pathways (e.g., nagA gene).
• Design and synthesis of chimeric antisense oligonucleotides with dual chemical modifications.
• Delivery of antisense oligonucleotides using cell-penetrating oligopeptides.
• Evaluation of bacterial growth inhibition and minimum inhibitory concentration (MIC80).

Main Results:

• Combined antisense oligonucleotides completely blocked glucosamine-6-phosphate synthesis.
• Targeting the glmS riboswitch alone was sufficient to inhibit S. aureus growth.
• The glmS riboswitch targeting oligonucleotide demonstrated a MIC80 of 5 μg/mL.
• Cell-penetrating oligopeptide facilitated intracellular delivery.

Conclusions:

• The glmS ribozyme is a highly suitable target for developing novel antisense oligonucleotide-based antibacterial drugs.
• Chimeric antisense oligonucleotides, particularly those targeting glmS, show significant potential against S. aureus.
• This strategy offers a promising avenue for combating multidrug-resistant bacterial infections.